Seongseok R. Yun

Hematology | Oncology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.

Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Journal: Journal of the American Heart Association
Published: May 06, 2026

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Journal: Annals of hematology
Published: April 02, 2026

Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma.

Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma.

Journal: Journal of managed care & specialty pharmacy
Published: March 26, 2026

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Journal: Blood neoplasia
Published: September 08, 2025

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Journal: Cardio-oncology (London, England)
Published: August 23, 2025

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Journal: Blood cancer discovery
Published: June 03, 2025

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival.

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 23, 2025

Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).

Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).

Journal: Leukemia research
Published: October 15, 2024

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.

Journal: Blood neoplasia
Published: August 22, 2024
Showing 1-12 of 88

Last Updated: 09/26/2026